DrugPatentWatch Database Preview
Lumasiran sodium - Generic Drug Details
» See Plans and Pricing
What are the generic drug sources for lumasiran sodium and what is the scope of patent protection?
Lumasiran sodium
is the generic ingredient in one branded drug marketed by Alnylam Pharms Inc and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.Lumasiran sodium has eighty-two patent family members in twenty-five countries.
Summary for lumasiran sodium
| International Patents: | 82 |
| US Patents: | 10 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | lumasiran sodium at DailyMed |
US Patents and Regulatory Information for lumasiran sodium
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for lumasiran sodium
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Eurasian Patent Organization | 201790789 | Start Trial |
| Canada | 2963843 | Start Trial |
| European Patent Office | 3087184 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2008131419 | Start Trial |
| European Patent Office | 3204015 | Start Trial |
| European Patent Office | 3156077 | Start Trial |
| Canada | 2708153 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
